{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:07:44Z","timestamp":1772579264093,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.lungcan.2022.12.004","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T02:02:03Z","timestamp":1670896923000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Assessment of RANK\/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial"],"prefix":"10.1016","volume":"175","author":[{"given":"Solange","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Letovanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urania","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunson","family":"Ejedepang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Biernat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Bubendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Warth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saraswati","family":"Pokharel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Majem Tarruella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Casas-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi","family":"Tsourti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesa","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roswitha","family":"Kammler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf. A.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.12.004_b0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nat. Rev. Immunology"},{"key":"10.1016\/j.lungcan.2022.12.004_b0010","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/0008-5472.CAN-09-4290","article-title":"Requirement of the NF-\u03baB subunit p65\/RelA for K-Ras\u2013induced lung tumorigenesis","volume":"70","author":"Bass\u00e8res","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2022.12.004_b0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature08462","article-title":"Requirement for NF-\u03baB signalling in a mouse model of lung adenocarcinoma","volume":"462","author":"Meylan","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0020","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.lungcan.2022.12.004_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","article-title":"The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development","volume":"103","author":"Fata","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2022.12.004_b0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0040","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2022.12.004_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.12.004_b0060","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1101\/gad.304162.117","article-title":"RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer","volume":"31","author":"Rao","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.lungcan.2022.12.004_b0065","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0075","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000320","article-title":"Lungscape: resected non\u2013small-cell lung cancer outcome by clinical and pathological parameters","volume":"9","author":"Peters","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0080","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2021.09.002","article-title":"Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP\/EORTC SPLENDOUR and AMGEN-249 trials","volume":"161","author":"Peters","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.12.004_b0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.12.004_b0095","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2013.54.5921","article-title":"Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project","volume":"32","author":"Blackhall","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0100","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jtho.2018.08.2034","article-title":"Computer-based intensity measurement assists pathologists in scoring phosphatase and tensin homolog immunohistochemistry \u2014 Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort","volume":"13","author":"Rulle","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.12.004_b0110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41379-019-0383-9","volume":"33","author":"Thunnissen","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdx629","article-title":"Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project","volume":"29","author":"Kerr","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12094-013-1137-7","article-title":"Lung cancer in women: an overview with special focus on Spanish women","volume":"16","author":"Remon","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.lungcan.2022.12.004_b0125","doi-asserted-by":"crossref","unstructured":"M. Beleut, R.D. Rajaram, M. Caikovski, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 2989-2994.","DOI":"10.1073\/pnas.0915148107"},{"key":"10.1016\/j.lungcan.2022.12.004_b0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2022.12.004_b0135","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.12.004_b0140","doi-asserted-by":"crossref","first-page":"e1480301","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.lungcan.2022.12.004_b0145","doi-asserted-by":"crossref","unstructured":"M.L. Cheng, L. Fong. Effects of RANKL-targeted therapy in immunity and cancer. Front. Oncol. 329 (2014).","DOI":"10.3389\/fonc.2013.00329"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222007139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222007139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:24Z","timestamp":1759237464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222007139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":29,"alternative-id":["S0169500222007139"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.12.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of RANK\/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}